Page 112 - Neuropsychiatric.indd

76. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142:1137-45. 94. Martino D, Karnik V, Osland S, Barnes TRE, Pringsheim TM. Movement disorders associated
77. Velamoor VR. Neuroleptic malignant syndrome. recognition, prevention and management. with antipsychotic medication in people with schizophrenia: an overview of Cochrane

Drug Saf. 1998;19(1):73-82. reviews and meta-analysis. Can J Psychiatry. 2018;63(11):706743718777392.
78. ศรินทิพย์ ศิริสุวรรณรัตน์. กลุ่มอาการ Neuroleptic malignant syndrome: การทบทวนเอกสารและ 95. Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The Safety of Metoclopramide
รายงานผู้ป่วย 6 ราย. วารสารโรงพยาบาลเจริญกรุงประชารักษ์. 2563;16(1):1-23. in Children: A Systematic Review and Meta-Analysis. Drug Saf. 2016;39(7):675-87.
79. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert 96. Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, Díez-Fernández A, Notario-

Opin Drug Saf. 2008;7(5):587-96. Pacheco B. Risk of extrapyramidal side effects comparing continuous vs. bolus intravenous
80. Boyer EW. Serotonin syndrome (serotonin toxicity). [accessed 29 November 2020]. metoclopramide administration: a systematic review and meta-analysis of randomised
Available from: https://www.uptodate.com/contents/serotonin-syndrome-serotonin- controlled trials. J Clin Nurs. 2015;24(23-24):3638-46.

toxicity#H7 97. Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The safety of prochlorperazine
81. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity in children: a systematic review and meta-analysis. Drug Saf. 2016;39(6):509-16.
Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 98. Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L, et al. The
2003;96(9):635-42. assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry. 2018;63(11)
82. Ellahi R. Serotonin syndrome: A spectrum of toxicity. BJPsych Advances. 2015;21(5), 324- :719-29.

32. 99. Tachere RO, Modirrousta M. Beyond anxiety and agitation: A clinical approach to akathisia.
83. Ables AZ, Nagubilli R. Prevention, diagnosis, and management of serotonin syndrome. Am Aust Fam Physician. 2017;46(5):296-8.
Fam Physician. 2010;81(9):1139-42. 100. Grover S, Sahoo S. Clozapine induced akathisia: a case report and review of the evidence.

84. Liu Y, Yang H, He F, Xu P, Tong H, Liu Y, et al. An atypical case of serotonin syndrome with Indian J Pharmacol. 2015r;47(2):234-5.
I
normal dose of selective serotonin inhibitors: A case report. Medicine (Baltimore). 101. biloglu AI. Metoclopramide induced akathisia: A case report. Bulletin of Clinical
2019;98(19):e15554. Psychopharmacology. 2013;23(2):186-9.
85. Tinroongroj N, Sukonthasarn A. Serotonin syndrome: a case report. BKK Med J.2016; 102. ปิยะณัฐ วงศ์วรรณ, ปรียา จาโกต้า, สุรัตน์ สิงห์มณีสกุลชัย, รุ่งโรจน์ พิทยศิริ. Dystonia for internist. ใน

้
12(1):58. กมล แกวกตณรงค และคณะ, บรรณาธิการ. Comprehensive review in internal medicine.
์
ิ
ิ
86. Chen JJ, Dashtipour K, Swope DM. Chapter 12 Movement disorder. In: Tisdale JE et al., eds. กรุงเทพมหานคร: บริษัท ปริ้นท์แอนด์มอร์ จ ากัด, 2563.
Drug-Induced Diseases: Prevention, Detection, and Management. 3rd ed. United States: 103. Oyewole A, Adelufosi A, Abayomi O. Acute dystonic reaction as medical emergency: a
American Society of Health-System Pharmacists, Inc., 2018. report of two cases. Ann Med Health Sci Res. 2013;3(3):453-5.
87. D'Souza RS, Hooten WM. Extrapyramidal symptoms. [accessed 29 November 2020]. 104. Blanchet P, Kivenko V. Drug-induced parkinsonism: diagnosis and management. Research
Available from: https://www.ncbi.nlm.nih.gov/books/NBK534115/ and Reviews in Parkinsonism. 2016;6:83-91.
88. Claxton KL, Chen JJ, Swope DM. Drug-induced movement disorders. J Pharm Pract. 105. Hattasin K, Kaewvichit S, Nitwatananun W, Ruengorn C. Modification and evaluation of
2007;20(6):415-29. tools for pharmaceutical care of patients with schizophrenia in non-psychiatric hospitals.

89. Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin. Songklanakarin J. Sci. Technol. 2018;40(3):550-4.
2015;33(1):153-74. 106. Brugger F, Bhatia KP, Besag FM. Valproate-Associated Parkinsonism: A Critical Review of the
90. Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr. 2019;42(2):56-61. Literature. CNS Drugs. 2016;30(6):527-40. doi: 10.1007/s40263-016-0341-8. PMID: 27255404.
91. David M. Gardner and Michael D. Antipsychotics and their side effects. Cambridge: 107. Morabito BD, Paulison B. Drug-induced parkinsonism: A case report. Ment Health Clin.

Cambridge University Press, 2010. 2018;7(2):65-8.
92. Barnes TR: A Rating Scale for Drug-Induced Akathisia. Br J Psychiatry. 1989;154:672-6. 108. Metoclopramide. [accessed 2 October 2020]. Available from: https://reference.medscape.
93. Factor SA, Leffler JB, Murray CF. Drug-induced movement disorder: A clinical review. com/drug/reglan-metozolv-odt-metoclopramide-342051#5
[accessed 2 October 2020]. Available from: https://www.medscape.org/viewarticle/586881 109. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, Part 2: Treatment of tardive dyskinesia.

Drugs. 2016;76(7):779-87.

90 91
91